BRITISH PHARMACOPOEIA COMMISSION

Expert Advisory Group: Antibiotics

SUMMARY MINUTES

A meeting of Expert Advisory Group: Antibiotics was held via videoconference on Wednesday 23rd September 2020.

Present: Dr R Horder *(Chair),* Dr G Cook (*Vice-chair*), Mr G Blake, Dr G Clarke, Mr E Flahive, Mr V Jaitely, Dr W Mann, Prof J Miller, Dr M Pires, Mr J Sumal, and Mr I Williams.

Apologies: NA

In attendance: Mr S Maddocks, Dr H Bowden, Ms K Busuttil and Ms M Nanasi. The group were also joined by Mr P Crowley and Ms K Nordgven for the item under minute 485.

470 Introductory remarks

Welcome The Chair welcomed Ms Busuttil and Ms Nanasi from the BP Laboratory.

Membership Members were asked to let the Secretariat know if any of their details had changed.

Expense Claims These should be sent to the Secretariat by email. Members were reminded that they were entitled to collect fees for meetings held via teleconference and further information would be shared by the Secretariat following the meeting.

471 General Matters ABS(20)13

Declaration of Interests Members were reminded to declare specific interests as they arose during the meeting and to inform the Secretariat of any changes to their interests throughout the year.

Freedom of Information Members were reminded that any FOI queries that they receive from the media were to be referred to the Secretariat.

472 MINUTES ABS(20)14

The minutes and summary minutes for the meeting held on 31st March 2020 were confirmed without comment.

473 MATTERS ARISING FROM THE MINUTES ABS(20)15

The Secretariat proposed a new format for the matters arising paper which was presented to the group. This new format involved the presentation of the matters arising from the meeting held immediately prior to the current meeting, along with any new or changed matters for the attention of the EAG.

The group agreed to the new format.

The following matters arising from the meeting held on 31st March 2020 were noted.

Rifaximin Tablets (minute 475 refers) The Secretariat had gained contact with a tablets manufacturer who had offered to carry out a review of the draft monograph. The

Secretariat would postpone laboratory work for the ID until these discussions had been carried out.

Cefalexin Preparations (minute 476 refers) The Secretariat were awaiting data from manufacturers with regard to a suitable dissolution method for all preparations prior to preparing the Tablets and Capsules monographs for public consultation. A laboratory report is pending for the Related substances of the oral solution monograph.

Tylosin Preparations (minute 477 refers) The Secretariat would prepare the Tylosin preparation monographs for public consultation and publication subject to comments.

Flucloxacillin Preparations (minute 479 refers) The Secretariat would prepare the monographs for public consultation following the receipt of dissolution data from manufacturers. A laboratory report is pending for the ID, Dissolution, Related substances and Assay methods for all monographs.

474 LABORATORY QUEUE REVIEW ABS(20)16

The Secretariat outlined a process that was employed to review items on the laboratory queue which involved reviewing the monographs in depth and re-evaluating the risk for lab work based on factors including the number of MAH, formulation review and current and proposed method differences.

The Secretariat were able to identify the monographs that did not require lab work, those that could benefit from MAH consultation and those monographs that still required some lab work.

Members agreed that the Amoxicillin Injection, Co-Amoxiclav Injection, Vancomycin Oral solution and Vancomycin Infusion monographs were suitable to be presented for public consultation.

Editorial comments were submitted via the BP website's Document Review Tool for all monographs and the Secretariat would amend prior to publication.

Amoxicillin Injection, Co-Amoxiclav Injection These monographs had been presented to the group in 2018. Members agreed that the monographs be sent for public consultation once the API monograph for Amoxicillin Sodium was published.

Vancomycin Oral solution, Vancomycin Infusion These monographs had been presented to the group in 2018 and had been agreed for laboratory evaluation. An alternative combined related substances and Vancomycin B method had been proposed for both monographs, based upon the Ph Eur monograph.

The limits had been proposed to harmonise with the Ph Eur monograph also, which would be slightly tighter than the currently published monographs and would be subject to public consultation.

Members agreed that the monograph did not require laboratory evaluation and should be submitted for public consultation.

MONOGRAPHS FOR THE BP 2022

475 Pivmecillinam Tablets (New) ABS(20)17

The draft monograph would be included in a future BP publication, subject to comments from manufacturers.

476 Tacrolimus Ointment (New) ABS(20)18

The draft monograph would be included in a future BP publication, subject to comments from manufacturers.

MONOGRAPHS FOR THE BP 2023+

477 Ofloxacin preparations ABS(20)19

The draft monograph would be included in a future BP publication, subject to comments from manufacturers.

478 Levofloxacin Preparations ABS(20)20

The draft monograph would be included in a future BP publication, subject to comments from manufacturers.

479 Clarithromycin preparations (Revised) ABS(20)21

The Clarithromycin Granules for oral suspension monograph had been published in the BP in 2017 and following this publication the Secretariat had been in communication with a manufacturer, who highlighted potential issues with the related substances method.

Data had been received from the manufacturer for an alternative related substances method for the Granules for oral suspension product. As a result of improved chromatography, the method had been drafted into all clarithromycin finished product monographs and were presented to the group.

Editorial comments were agreed, and the monographs would be amended prior to publication.

Identification (Granules for oral suspension) The published granules for oral suspension monograph used two identification tests; infra-red and retention time comparison. Members agreed to delete the secondary identification test as the infra-red was considered suitably discriminatory.

Dissolution (tablets) It was noted that the currently published clarithromycin tablets monograph did not contain a limit requirement for the dissolution test.

A limit of 80% (Q) in 30 minutes was proposed, based on licensed specifications, and would be published for public consultation.

Related substances (all) The Secretariat received HPLC and UHPLC methodology from an MAH. The data showed improved chromatography using the U(H)PLC method above the HPLC and the currently published HPLC procedures therefore, this was presented to the members in the draft monographs.

Members agreed to the adoption of the new related substances method as drafted.

Laboratory evaluation The Secretariat had carried out a laboratory risk assessment for the monographs and it was agreed that the Granules for Oral suspension monograph, related substances method would be tested by the laboratory.

The infusion, prolonged-release tablets and tablets monographs were to be published in the BP 2022 subject to public consultation.

V MONOGRAPHS FOR OMMISSION

480 Cefalonium API and Infusion ABS(20)22

Based on the availability of Cefalonium CRS, it had originally been proposed by the Secretariat to omit the monographs for Cefalonium API and Cefalonium Intramammary Cow Infusion from the BP 2022 (VET).

Following confirmation that the VMD had a number of registered products for Cefalonium it was agreed to keep the monographs and add both to the work programme.

The members agreed that the monographs should remain in the publication and that they should be added to the work programme to be revised at the earliest opportunity.

FOR INFORMATION

481 Out of Stock BPCRS report ABS(20)23

The out of stock BPCRS for monographs under the remit of EAG ABS were presented to the group.

The Secretariat agreed to work with veterinary license holders and the VMD to obtain material for the establishment of the Cefalonium BPCRS or alternatively to revise the monograph.

482 Work Programme ABS(20)24

The EAG ABS work programme was presented to the members for discussion.

Following a series of streamlining actions over the preceding 3 years, the work programme was in a place where it could accept more substantial additions, members were introduced to potential options of projects to the work programme over the coming years.

The group were reminded of the discussions from February 2019 regarding the alignment of BNF chapter 5 products with the EAG, discussions were ongoing with respect to these monographs, the Secretariat agreed that the members would be kept apprised of the progress of these discussions.

Veterinary monographs The Secretariat had opened further communication and information sharing streams with the VMD to build on the Veterinary monograph portfolio.

Aminoglycoside antibiotic product monographs Members were informed of the quarterly consultation period where the BP were asking for opinion on the adoption of HPLC with Pulsed Amperometric Detection capabilities in the pharmacopoeia.

An update on the adoption of this test would be presented at a future meeting of the EAG subject approval.

483 British Pharmacopoeia Matters ABS(20)25

The Secretariat highlighted the recent work of the British Pharmacopoeia including a key update to the BP Website and recruitments within the BP Secretariat.

BP Website
The group were informed of the successful BETA phase of the Tracked Changes project and the release of the full version to the BP 2021 content.

Appointments in the British Pharmacopoeia Secretariat
Members were introduced to changes within the Secretariat and were made aware of specific points of contact for the EAG.

484 European Pharmacopoeia Matters ABS(20)26

An informal report from the 167th meeting of experts Group 7 was presented to the EAG.

There were no monographs for comment on Pharmeuropa 32.2 that were under the remit of the EAG. The Secretariat thanked the experts for their support to the UK Delegation.

485 Update to Bacterial Endotoxins Test ABS(20)27

The European Pharmacopoeia had adopted a new general chapter titled “Test for Bacterial Endotoxins using Recombinant Factor C” at their 165th session which had been published in July 2020 with an effective date of 1st January 2021.

Members were introduced to the text and made aware of potential impact to monographs.

486 Analytical Quality by Design Update ABS(20)28

The last update from the Analytical Quality by Design (AQbD) project was given to EAGs in 2019. A full stakeholder consultation was then carried out and an official report produced by the MHRA.

The Agency response
There was a clear preferred direction for the inclusion of AQbD in the Pharmacopoeia, the Secretariat noted that the responses called for additional supporting information to be included alongside the specific monographs. Therefore, the strategy incorporates the development and subsequent publishing of new standards and guidance to support the needs of the users of the BP, including general guidance and pharmacopeial monographs.

V ANY OTHER BUSINESS

487 **Tylosin product monographs** A member introduced work being performed on the proposed Tylosin monographs. The monographs would be published in a future edition of the BP.

VI DATE OF NEXT MEETING

4th March 2021.